LifeSpan, Pfizer Announce Collaboration to Develop Pathology Systems

LifeSpan Biosciences has entered into an agreement with Pfizer to develop an automated pathology system for rapid and accurate evaluation of tissue specimens in preclinical studies.

The system developed by LifeSpan will use enhanced image capture and artificial intelligence computer analysis software to evaluate stained tissue specimens for quality and tissue abnormalities. The automated system will assist pathologists, increasing their accuracy and productivity.

"We believe that through this collaboration, LifeSpan can apply its automated pathology ALIAS system to the pharmaceutical sector to help bring safe and effective therapies to market sooner," said Glenna Burmer, LifeSpan's chief scientific officer. LifeSpan is currently developing a system for automated cancer recognition, and the collaboration is an extension of its capabilities in the automated pathology area.